{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=22",
    "query": {
      "condition": "Ovarian Cancer",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 2465,
    "total_pages": 247,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T00:12:57.262Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02764333",
      "title": "TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TPIV200",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2016-05-06",
      "completion_date": "2021-01-20",
      "has_results": true,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02764333"
    },
    {
      "nct_id": "NCT00317434",
      "title": "Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 90 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2005-11",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2009-12-15",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00317434"
    },
    {
      "nct_id": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Prostate Cancer",
        "Uterine Cancer",
        "Cervix Cancer",
        "Ovarian Cancer",
        "Kidney Cancer",
        "Bladder Cancer",
        "Thyroid Cancer",
        "Melanoma",
        "Sarcoma",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Refractory Cancer",
        "Non Small Cell Lung Cancer",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "SNS-101 (anti-VISTA)",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sensei Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2023-05-31",
      "completion_date": "2026-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05864144"
    },
    {
      "nct_id": "NCT00002734",
      "title": "Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "lutetium Lu 177 monoclonal antibody CC49",
          "type": "RADIATION"
        },
        {
          "name": "yttrium Y 90 monoclonal antibody CC49",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "1996-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002734"
    },
    {
      "nct_id": "NCT01670799",
      "title": "Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "Ketorolac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2012-03",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670799"
    },
    {
      "nct_id": "NCT02015416",
      "title": "A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Non-small Cell Lung Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "IDC-G305",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-11",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02015416"
    },
    {
      "nct_id": "NCT00003811",
      "title": "Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Germ Cell Tumor",
        "Drug/Agent Toxicity by Tissue/Organ",
        "Extragonadal Germ Cell Tumor",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "bleomycin sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "Up to 14 Years"
      },
      "enrollment_count": 27,
      "start_date": "2000-04",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-04",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 97,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003811"
    },
    {
      "nct_id": "NCT00431054",
      "title": "Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Perifosine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2007-02",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2016-02-19",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00431054"
    },
    {
      "nct_id": "NCT00550654",
      "title": "Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Melanoma (Skin)",
        "Metastatic Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "hypofractionated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "image-guided radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "tomotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2007-10",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00550654"
    },
    {
      "nct_id": "NCT02227654",
      "title": "Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Abnormal Ovarian Ultrasound",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Frederick R. Ueland, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "25 Years and older · Female only"
      },
      "enrollment_count": 179,
      "start_date": "2016-09-12",
      "completion_date": "2022-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-03-02",
      "last_synced_at": "2026-10-29T00:12:57.262Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227654"
    }
  ]
}